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1. Introduction
Infectious diseases caused by parasites are a major threat for entire mankind, especially in
the tropics. These infections are not only restricted to humans, they are also predominant in
animal health. Just a few years ago infectious diseases caused by parasites were classified as
an issue of the past. Due to the elevating level of drug resistance of these pathogens against
the current chemotherapeutics, the need for new drugs became even more important. In
particular parasitic diseases such as malaria, leishmaniasis, trypanosomiasis, amoebiasis, tri‐
chomoniasis, soil-transmitted helminthiasis, filariasis and schistosomiasis are major health
problems, especially in “developing” areas (Renslo and McKerrow, 2006; Pal and Bandyo‐
padhyay, 2012). A variety of these parasitic diseases, which comprises the so called neglect‐
ed diseases Chagas disease, leishmaniasis, sleeping sickness, schistosomiasis, lymphatic
filariasis, onchocerciasis and of course malaria (Chatelain and Ioset, 2011), are transmitted
by vectors and therefore attempts to combat transmission became prominent. In contrast to
the treatment of bacterial infections with antibiotics there are no “general” antiparasitic
drugs. The use of a specific drug is dependent on the parasitic organism and therefore has to
be individually chosen (Khaw et al., 1995).
Reactive oxygen species (ROS) and oxidative stress are the inevitable consequences of aero‐
bic metabolism, with partially reduced and highly reactive metabolites of O2 being formed
in the mitochondria (Andreyev et al., 2005) or as by-products of other cellular sources such
as the cytoplasm, the endoplasmatic reticulum, the plasma membrane and peroxisomes.
Furthermore, environmental agents such as ionizing and UV radiation or xenobiotic expo‐
sure can generate intracellular ROS. O2 metabolites include superoxide anion (O2-) and hy‐
drogen peroxide (H2O2), formed by one- and two electron reductions of O2 or the highly
reactive hydroxyl radical (‧OH) which is formed in the presence of metal ions via Fenton
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and/or Haber-Weiss reactions (Massimine et al., 2006). At physiologically low levels, ROS
can function as second messenger in redox signaling, with H2O2 best providing the specifici‐
ty in its interaction with effectors in signaling processes (Forman et al., 2010). Balancing the
generation and elimination of ROS maintains the proper function of redox-sensitive signal‐
ling proteins. However, severe increases of ROS induce oxidative modifications in the cellu‐
lar macromolecules DNA, proteins and lipids, this leading to a disruption of redox
homeostasis and irreversible oxidative damage (Trachootham et al., 2008). Depending on
the cellular context, the levels of ROS and the redox state of the cells, alterations of the deli‐
cate redox balance can promote cell proliferation and survival or induce cell death.
To maintain redox homeostasis and eliminate ROS, aerobes are equipped with enzymatic/
nonenzymatic antioxidants and metal sequestering proteins to either prevent or intercept
the formation of pro-oxidants. Furthermore, protective mechanisms are put in place to re‐
pair and replace damaged macromolecules. Two central thiol/disulfide couples are involved
in controlling the redox state of the cell: glutathione/glutathione disulfide (GSH/GSSG) is the
major redox couple that determines the antioxidative capacity of cells, other redox couples
include the active site dithiol/disulfide of thioredoxins (Trxred/Trxox) interacting with a differ‐
ent subset of proteins and thus forming a distinct but complementary redox system (Jones
and Go, 2010).
Enzymatic antioxidants can be categorized into primary or secondary antioxidants, the first
reacting directly with pro-oxidants (e.g. catalase, superoxide dismutase), the latter are in‐
volved in the regeneration of low molecular weight antioxidant species (Halliwell, 1999).
Here, the reduced state of GSSG and Trx-enzymes is restored by the glutathione reductase
(GSR) and the Trx reductase using electrons obtained from NADPH. Additionally glutare‐
doxins (Glrx) utilize GSH for the reduction of intracellular disulfides (Fernandes and
Holmgren, 2004). While Trx, Trx reductase and Trx peroxidase (peroxiredoxin, Prx) consti‐
tute the Trx-system, the versatile GSH-system includes enzymes required for GSH synthesis
and recycling, for its use in metabolism, in defense against ROS-induced damage and in a
multitude of detoxification processes. Furthermore, for normal GSH turnover and disposi‐
tion of GSH-conjugated metabolites and xenobiotics, export from the cell is required that is
carried out by GSH efflux transporters and pumps (Sies, 1999) (Fig. 1).
In spite of the diversity of parasites, all are faced with similar biological problems that are
related to their lifestyle. Besides coping with ROS levels generated from intrinsic sources, all
have to deal with the oxidative stress imposed by the host´s immune response. Furthermore,
parasites are faced with ROS that are produced during the epithelial innate immune re‐
sponse of their vector, by vector-resident gut bacteria (Cirimotich et al., 2011) or during mel‐
anotic encapsulation processes (Kumar et al., 2003).
Since the redox system plays such a fundamental and indispensable role for parasite surviv‐
al within their host (Massimine et al., 2006), drugs that either promote ROS generation or
inhibit cellular antioxidant systems will lead to redox imbalance by pushing ROS levels
above a certain threshold level that will ultimately lead to parasite death (Müller et al.,
2003). In general, drugs that target vital redox reactions or promote oxidative stress are
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named redox-active antiparasitic drugs (Seeber et al., 2005) on which we will mainly focus
within this chapter.
2. The role of the antioxidant system in Leishmania
Leishmaniasis is caused by the protozoan flagellate Leishmania which is transmitted by sand‐
flies of the genus Phlebotomus (Sharma and Singh, 2008). There are several species of the ge‐
nus Leishmania which are known to cause this infectious disease. Leishmaniasis shows a
broad spectrum of clinical manifestations and includes visceral, cutaneous and mucocutane‐
ous leishmaniasis. Whereas the two latter ones are not considered to be lethal (Herwaldt,
1999), infection with Leishmania donovani/infantum – resulting in kala azar or visceral leish‐
maniasis - can be lethal without treatment. Although treatment of leishmaniasis with che‐
motherapeutics is the only current option, drug resistance to first-line drugs is increasing
which is accompanied by frequently occurring toxic side effects and by the high cost of
treatment (Van Assche et al., 2011). Additionally, the small number of novel drugs com‐
bined with the low number of identified and subsequently validated number of Leishmania
drug targets in clinical use, reveals an alarming situation for the current status in chemother‐
apy. The predominant target for the application of chemotherapy is the amastigote stage
which proliferates intracellularly in tissue macrophages (Dedet et al., 2009), thereby hinder‐
ing the accessibility of antileishmanial drugs to the pathogen.
3. Antimonials
Despite the fact that antimonials were already identified in 1921, they still remain the first-
line treatment, although the precise mode of action is not known. But it is generally accepted
that pentavalent antimonials (SbV) represent a pro-drug which is converted to trivalent anti‐
monials (SbIII) for antileishmanial activity. Recently it has been indicated that thiols act as re‐
ducing agents in this conversion. Furthermore, the participation of a unique parasite-specific
trimeric glutathione transferase TDR1 in the activation of antimonial prodrugs has been sug‐
gested (Fyfe et al., 2012).
Treatment with antimonials requires parenteral administration and is accompanied by toxic
side effects such as cardiac arrhythmia and acute pancreatitis (Sundar and Rai, 2002). Some
studies have been carried out to investigate the activity mechanism of antimonials which
correlates with an interference with the antioxidant defence system of the parasite: Trivalent
antimonials decrease the thiol-reducing capacity of Leishmania by inducing an efflux of try‐
panothione. In contrast to Leishmania, mammalian cells depend on GSH to control their in‐
tracellular thiol-redox status. Here, ROS and oxidized cell components are efficiently
reduced by GSH, thereby generating GSSG. The glutathione disulfide form can then be re‐
generated by the GSR (Monostori et al., 2009). In contrast, the redox metabolism of Leishma‐
nia relies on a modified GSH-system, N1,N8-bis(l-γ-glutamyl-l-hemicystinylglycyl)
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spermidine, also known as trypanothione (Fairlamb et al., 1985). The oxidised form, trypa‐
nothione disulfide, is generated when trypanothione reduces ROS and its reconversion is
catalysed by the trypanothione reductase. Antimonials inhibit this enzyme, leading to an ac‐
cumulation of trypanothione disulfide, which subsequently is not accessible for the reduc‐
tion of ROS (Krauth-Siegel and Comini, 2008). The influence of antimonials on the parasite's
redox biology has been verified on cellular level by the fact that trivalent antimonials-resist‐
ant parasites display an increased IC50-value for nitric oxide donors such as NaNO2, SNAP,
and DETA NONOate compared to antimonial-sensitive strains (Souza et al., 2010; Holzmül‐
ler et al., 2005; Vanaerschot et al., 2010). Whether nitric oxide resistance is due to elevated
trypanothione levels or due to another antioxidant mode of action is not yet clear.
4. Amphotericin B
Amphotericin B (Fig. 2), a polyene macrolide, has been employed in the treatment of Leish‐
mania since 1960, but just as a second-line drug. This drug exhibits an excellent antileishma‐
nia activity with more than 90% cure rates. Because the pure compound creates severe side
effects and requires long-term treatment and extensive monitoring, liposomal application of
amphotericin B is used at the moment which results in cure rates of 3–5 days (up to 100%), is
convenient for the patient and is less expensive (Gradoni et al., 2008; Manandhar et al., 2008;
Sundar et al., 2002; Thakur et al., 1996). The mode of action can be explained based on its
chemical structure, polyene macrolide has been shown to bind to ergosterol, one of the main
sterols within Leishmania membranes. Interference with this molecule results in an increas‐
ing permeability of the cell membrane which leads to the parasite’s death (Balana-Fouce et
al., 1998; Amato et al., 2008). Additionally there is some evidence that amphotericin B has an
effect on the oxidative response of macrophages (Mukherjee et al., 2010), however further
experiments are required to verify this effect.
5. Miltefosine
Miltefosine (hexadecylphosphocholine) is the first and currently the only, orally adminis‐
tered antileishmanial drug (Fig. 2). However, despite cure rates of up to 98% (Roberts, 2006),
the drug reveals serious side effects such as vomiting, diarrhea and can cause abnormal
physiological development of the foetus. Furthermore, the drug has a relatively long half-
life of about 150 hours (Seifert et al., 2007; Maltezou, 2010) which could lead to the develop‐
ment of rapid resistance. Related to its structure, the drug possibly interferes with
membranes and membrane-linked enzymes. Currently no verified implications of the drug
within the redox biology of the parasite have been found (Rakotomanga et al., 2004; Saint-
Pierre-Chazalet et al., 2009).
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6. Oxidative chemotherapeutic intervention
of Trypanosoma infections
Trypanosoma  infections,  caused  by  the  flagellate  protozoan  Trypanosoma  are  responsible
for  a  high  degree  of  health  problems  in  endemic  countries.  They  can  be  divided  into
two types  of  pathogens:  Trypanosoma  cruzi,  the  causative  agent  of  Chagas  disease,  also
known as  American trypanosomiasis,  since  it  occurs  in  Latin  America  and Trypanosoma
brucei  ssp.,  the  causative  agent  of  sleeping  sickness,  or  human African  trypanosomiasis,
since it is endemic to sub-Saharan Africa. The current medication is known for its toxici‐
ty, poor activity in immune-suppressed patients and long-term treatment combined with
high costs. Moreover, vaccines are not foreseeable in the near future. The T. cruzi life cy‐
cle includes three fundamental forms characterized by the relative positions of the flagel‐
lum, kinetoplast and nucleus: Trypomastigotes,  epimastigotes and amastigotes,  the latter
one  characterized  by  their  proliferation  in  any  nucleated  cell  (Prata,  2001).  On  the  one
hand  Chagas'  disease  is  controlled  through  elimination  of  its  vectors  by  using  insecti‐
cides and on the other side by chemotherapy.  Currently,  the drugs used are nifurtimox
(4[(5-nitrofurfurylidene)amino]-3-methylthiomorpholine-1,1-dioxide),  derived  from  nitro‐
furan, and benznidazole (N-benzyl-2-nitroimidazole-1-acetamide),  a nitroimidazole deriv‐
ative.  Nifurtimox and benznidazole (Fig.  2)  are trypanocidal to all  forms of the parasite
(Rodriques  Coura  and de  Castro,  2002).  However,  severe  side  effects  and toxicity  have
been observed (Kirchhoff, 2000). In addition, there are also reports of mutagenesis result‐
ing  in  DNA damage  (Zahoor  et  al.,  1987).  An  additional  aspect  that  complicates  treat‐
ment  is  the  different  susceptibility  of  different  parasite  strains  to  the  applied
chemotherapeutics  (Filardi  and  Brener,  1987).  The  mode  of  action  of  nifurtimox  and
benznidazole  (Fig.  2)  is  via  the  formation  of  free  radicals  and/or  charged  metabolites.
The nitro group of both drugs is reduced to an amino group by the catalysis of nitro-re‐
ductases,  leading  to  the  formation  of  various  free  radical  intermediates.  Cytochrome
P450-related  nitro-reductases  initiate  this  process  by  producing  a  nitro  anion  radical
(Moreno  et  al.,  1982).  Subsequently,  the  radical  reacts  with  oxygen,  which  regenerates
the  drug  (Mason  and  Holtzman,  1975).  For  example,  nifurtimox-derived  free  radicals
may undergo redox cycling with O2,  thereby producing H2O2  in a reaction catalysed by
the  SOD (Temperton et  al.,  1998).  Furthermore,  in  the  presence  of  Fe3+  the  highly  reac‐
tive ‧OH is also being formed according to the Haber-Weiss reaction. These free radicals
can subsequently bind to cellular macromolecules such as lipids,  proteins and DNA, re‐
sulting in severe damage of parasitic cells (Díaz de Toranzo et al.,  1988). In contrast, the
trypanocidal effect of benznidazole does not depend on ROS but it is likely that reduced
metabolites  of  benznidazole  are  covalently  binding  to  cellular  macromolecules,  thereby
revealing their trypanocidal effect (Díaz de Toranzo et al., 1988; Maya et al., 2004). Addi‐
tionally,  it  has  been  demonstrated  that  benznidazole  inhibits  the  T.  cruzi  NADH-fuma‐
rate reductase (Turrens et al., 1996).
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7. Approaches to increase oxidative stress within the malaria parasite
Malaria is a devastating and quite often a deadly parasitic disease, which causes important
public health problems in the tropics. The population in more than 90 countries, with more
than 2000 million citizens, is exposed to the infection. Malaria infection is responsible for an
estimated 500 million clinical cases per annum, causing more than one million deaths; most
of these are children in Africa. The malaria parasite Plasmodium falciparum, the causative
agent of Malaria tropica, is proliferating within human red blood cells, thereby exploiting
host’s nutrient sources and hiding from the human immune response. A vaccine is not avail‐
able and the control of the disease depends solely on the administration of a small number
of drugs. Due to mutational modification of the genome of the malaria parasite, an ongoing
rapid adaptation to environmental changes and drug resistance is occurring (Greenwood et
al., 2008). At the moment – which is just a question of time - solely artemesinin is still effec‐
tive against the malaria parasite. However, first reports already demonstrated drug resist‐
ance against artemisinin (Wangroongsarb et al., 2011). Therefore, continuous discovery and
development of new drugs are urgently needed. A variety of the current anti-malaria drugs
are targeting the redox balance of the parasite. As outlined above, redox systems are essen‐
tial for the intracellular proliferation of the plasmodial pathogen.
In general, P. falciparum uses the two interacting systems, GSH- and TRX-system, to protect
against reactive ROS (Kanzok et al., 2002; Kanzok et at., 2000; Kawazu et al., 2001; Kehr et
al., 2011; Krnajski et al., 2001; Krnajski et al., 2002; Kumar et al., 2008; Liebau et al., 2002).
Both systems can be link by the redox protein plasmoredoxin (Becker et al., 2003). Active in‐
terference by employing redox-active antiparasitic drugs, however, harms the parasite and
results in its death. Compounds which disturb the redox balance can be categorised into
three different groups: (i) molecules that are responsible for the de novo synthesis of ROS and
thus lead to parasite death, (ii) molecules which inhibit the activities of redox balancing en‐
zymes and (iii) molecules that interfere in the scavenging of pro-oxidant metabolic products
like hemozoin.
8. Molecules which inhibit the activities of redox balancing enzymes
The GSH-system plays an important role in the maintenance of the redox status in Plasmodi‐
um (Kehr et al., 2011). It is involved in detoxifying free heme (ferriprotoporphyrin IX)
(Atamna et al., 1995; Müller, 2003) and in the termination of radical-based chain reactions
(Frey, 1997). Therefore, enzymatic reactions within this system are highly druggable. The
GSR is one of the key enzymes of the GSH-system and consequently several compounds
have been synthesized to successfully interfere with its catalysis in vitro and in vivo (Biot et
al., 2004; Gallo et al., 2009; Grellier et al., 2010; Muller et al., 2011). Inhibitory compounds
comprise for example isoalloxazines, quinacrines, tertiary amides that reveal antimalarial ac‐
tivity at low doses against the chloroquine sensitive P. falciparum strain 3D7 (Sarma et al.,
2003; Friebolin et al., 2008; Chibale et al., 2001). Methylene blue (Fig. 2), a noncompetitive
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inhibitor of the P. falciparum GR, shows antiplasmodial activity against all blood stage forms,
whereas only a marginal cytotoxic effect against mammalian cells has been reported (Biot et
al., 2004; Buchholz et al., 2008; Atamna et al., 1996; Akoachere et al., 2005; Badyopadhyay et
al., 2004; Krauth-Siegel et al., 2005; Garavito et al., 2007).
The GST is one of the most abundant proteins expressed in P. falciparum. Additionally to its
detoxifying role, it efficiently binds parasitotoxic heme not only in the presence of GSH, but
also when GSSG is present, thereby protecting the parasite from hemin even under severe
oxidative stress conditions. Here, a peculiar loop region, that is both crucial for the gluta‐
thione-dependent tetramerization/inactivation process and for hemin-binding, represents an
ideal drug target (Liebau et al., 2005; 2009). Recently chemical synthesis to design effective
compounds to target GST has been performed which show some promising antiplasmodial
activity (Ahmad et al., 2007; Sturm et al., 2009). Furthermore, the development of drugs that
overcome resistance to available antimalarial drugs also are of great interest. The action of
multidrug resistance protein (MRP)-like transporters is associated with the efflux of xenobi‐
otics in both unaltered and GSH-conjugated form and it is conceivable that they are in‐
volved in the development of drug resistance in malarial parasites (Koenderink et al., 2010).
Since coordinated expression and synergistic interactions between GST and efflux pumps
have been observed (Sau et al., 2010), a promising new intervening strategy might be the in‐
hibition of GST and/or the development of GST-activated pro-drugs that overcome drug re‐
sistance by blocking the drug binding sites of the transporters.
Another promising antimalarial drug target is the P. falciparum TrxR (Banerjee et al., 2009).
Chalcone derivatives and Eosin B exhibit antiplasmodial activity by inhibiting the plasmo‐
dial TrxR (Li et al., 1995; Massimine et al., 2006).
For many years it was thought that the malaria parasite had no need for an endogenous
SOD and simply adopted the host´s enzyme for its purpose. However, in 2002, an iron-de‐
pendent SOD was described in P. falciparum (Boucher et al., 2006). Being quite distinct from
the human tetrameric Mn and Cu/Zn SOD, it is exploited as anti-malaria drug target (Sou‐
lere et al., 2003).
9. Drugs inhibiting hemozoin formation and thereby inducing oxidative
stress
Besides the attacks of the immune systems of the respective host, where ROS are deployed to
kill invading pathogens, the parasite faces another even bigger challenge: Plasmodium relies al‐
so on the digestion of human haemoglobin to obtain amino acids for its metabolism (Sherman,
1977). Haemoglobin is the major protein inside the erythrocyte and the parasite has evolved a
unique pathway to utilise this molecule (Muller et al., 2011). Heme is the degradation product
of haemoglobin, which has to be detoxified and stored as hemozoin within the food vacuole of
the parasite – the place where the haemoglobin degradation occurs. Non-detoxified heme is
extremely toxic (Papalexis et al., 2001) and leads not only to the generation of H2O2, ‧OH and O2-.
(Francis et al., 1997), but also to the highly reactive, non-radical molecule, singlet oxygen (1O2)
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(Freinbicherler et al., 2011). Moreover, one 1O2 molecule can be either synthesised by the reac‐
tion of ‧OH and O2-. or two O2-. with two hydrogen ions (Khan and Kasha, 1994). In order to de‐
toxify these ROS, Plasmodium has developed – as outlined above - multiple antioxidant defence
systems. However - excluding the membrane located lipophilic tocopherol (vitamin E) (Wang
and Quinn, 1999) - none of the above mentioned defense systems are capable to detoxify 1O2.
The fact that vitamin B6 is linked to the defense against 1O2 in plants and fungi (Tambasco-Stu‐
dart et al., 2005; Ehrenshaft et al., 1999), suggests that the vitamin B6 biosynthesis might also
play a yet unrecognized role in combating 1O2 in the malaria parasite P. falciparum. Very recent‐
ly this role of 1O2 detoxification has been verified in the malaria parasite (Wrenger et al., 2005;
Knöckel et al., 2012; Butzloff et al., 2012).
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Figure 1. Schematic illustration of the glutathione (GSH) system. GSH homeostasis involves intra- and extracellular
mechanisms. GSH is synthesized from amino acids (AA) by the action of γ-glutamylcysteine synthetase (γ-GCS) and
glutathione synthase (GSH-S), both requiring ATP. As antioxidant, GSH participates in the reduction of peroxides, cata‐
lysed by glutathione peroxidase (GPx), in the reduction of protein-disulfides, catalysed by glutaredoxins (Grx) and in
conjugation reactions with electrophils (eg. xenobiotics, X), catalysed by glutathione transferases (GSTs). The gluta‐
thione conjugates (GS-X) and GSSG are transported out of the cell via GS-X/GSSG pumps. The NADPH-dependent GSH
reductase (GR) is responsible for the intracellular recycling of GSH, while extracellular GSH gets sequentially hydro‐
lysed by γ-glutamyl transpeptidase (γ-GT) and dipeptidase (DPD), with glutamate, cysteine and glycine being recycled
for GSH synthesis (γ-glutamyl cycle).
A number of drugs have been identified that act as inhibitors of the hemozoin formation
by binding to  heme.  This  leads  to  an accumulation of  free  heme,  causes  high levels  of
oxidative stress  and ends in the death of  the parasite  (Meunier  et  al.,  2010).  Quinoline-
containing derivatives such as amopyroquine,  amodiaquine,  tebuquine,  halofantrine,  py‐
ronaridine,  quinine,  mepacrine,  epiquinine,  quinidine,  bisquinoline  chloroquine  (see
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figure  2)  are  highly  potent  antimalarials  that  inhibit  hemozoin formation at  EC50-values
in the low nano-molar range (Egan et al.,  2000; Kotecka et al.,  1997; O’Neill  et  al.,  2003;
Vennerstrom et  al.,  1992).  Azole  derivatives  are  also  inhibitors  of  the  hemozoin  forma‐
tion  and  reveal  efficacy  against  chloroquine  sensitive  as  well  as  resistant  plasmodial
strains (Banerjee et al., 2009; Rodrigues et al., 2011). Another novel class, which has been
identified  to  interact  with  heme and thereby prevent  the  hemozoin  formation,  are  xan‐
thones  (Docampo et  al.,  1990;  Ignatushchenko et  al.,  1997;  Xu Kelly  et  al.,  2001).  More‐
over,  a  variety of  isonitrile  derivatives gain their  antimalarial  activity from inhibition of
the hemozoin synthesis (Kumar et  al.,  2007;  Wright et  al.,  2001) resulting in EC50-values
in the low nano-molar range (Badyopadhyay et al., 2001; Singh et al., 2002; Kumar et al.,
2007).  Benzylmenadione  derivatives  do  not  show  any  cytotoxicity  against  two  human
cell  lines  while  they  are  effective  against  the  chloroquine  resistant  P.  falciparum  strain
Dd2  (Muller  et  al.,  2011).  The  precise  mode  of  action  of  benzylmenadione  remains  for
elucidation,  but  it  has  been suggested that  the molecule  is  initially  oxidized to  a  naph‐
thoquinone derivative within the food vacuole of  the parasite which leads subsequently
to the inhibition of the hemozoin formation (Davioud-Charvet et al., 2003).
10. Druggability of oxidative stress systems in helminths
Helminths are parasitic worms that encompass nematodes (roundworms), cestodes and
trematodes (flatworms) and affect humans in all areas of the world, with more than one-
third of humans harbouring these parasites that cause chronic, debilitating morbidity. Fur‐
thermore, co-endemicity and polyparasitism increase the burden of millions (Hotez et al.,
2008). In the absence of vaccines, control relies on pharmacotherapy and pharmacoprophy‐
laxis to easy symptoms and reduce transmission. Helminthosis are treated with a limited
number of anthelmintics by chemotherapy of symptomatic individuals or, more general, by
control programmes that rely on mass drug administration (MDA) and require annual or bi‐
annual treatment of at-risk populations over prolonged period of time (Prichard et al., 2012).
A major problem, however, is the development of resistance or tolerance by the parasites to
these common antiparasitic drugs (Vercruysse et al., 2011). It is therefore essential to under‐
stand the underlying mechanisms of drug resistance and find new drugs to circumvent it.
Praziquantel has been used for over 20 years to treat a variety of human trematode infec‐
tions. Its precise mechanism of action has not been fully elucidated, however, there is exper‐
imental evidence that praziquantel acts by increasing the permeability of cell membranes
towards calcium ions and/or by interfering with adenosine uptake (Jeziorski and Greenberg,
2006; Angelucci et al., 2007). Furthermore, it has been suggested that praziquantel reduces
GSH concentrations, making the parasite more susceptible to the host immune response
(Ribeiro et al., 1998). Interestingly, exposure to sub-lethal concentrations of praziquantel
shows that schistosomes undergo a transcriptomic response similar to that observed during
oxidative stress (Aragon et al., 2009).
Oxidative Stress in Human Infectious Diseases – Present and Current Knowledge About Its Druggability
http://dx.doi.org/10.5772/53758
235
Figure 2. Molecular structures of chemotherapeutics which are used to treat infectious disease by generating directly
or indirectly high levels reactive oxygen species.
Reliance on a single drug for mass treatment is risky. Therefore, anti-schistosomiasis drug
development is on the way to identify new compounds with different modes of action. Re‐
cently it was demonstrated that artemisinin-based compounds (e.g. artemether, figure 2) are
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active against immature stages of schistosomes. Although a number of potential drug tar‐
gets have been proposed, the mode of action remains ambiguous (O´Neill et al., 2010). It is
thought that the primary activator of the drug is an iron source. Therefore, interaction with
heme in the worm gut has been suggested, leading to the formation of an unstable species
that generates ROS and thus kills the worm (Utzinger et al., 2001). Since artemisinins are
critically important for malaria chemotherapy, they are not available for MDA.
Schistosomes seem to be poorly adapted to cope with oxidative stress. This is surprising,
since they have to deal with host-immune and self-generated ROS and, furthermore, with
ROS generated during the consumption of host haemoglobin (Huang et al., 2012).The highly
restricted antioxidant network has been widely accepted as an excellent drug target for
schistosomes and other platyhelminths, since it is unique and differs significantly from the
human host. Interestingly, the parasites have merged the Trx- and GSH-system using a hy‐
brid enzyme, the thioredoxin-glutathione reductase (TGR) (Salinas et al., 2004, Huang et al.,
2012). Using RNA interference, the TGR was found to be essential for parasite survival
(Kuntz et al., 2007). TGR was indicated to be the main target of schistosomicidal drugs used
in the past (antimonyl potassium tartrate and oltipraz) and of the anti-arthritic drug aurano‐
fin (Fig. 2), with a significant worm reduction observed in infected mice (Kuntz et al., 2007;
Angelucci et al., 2009). A quantitative high-throughput screen identified highly potent lead
compounds against the Schistosoma TGR (Simeonov et al., 2008), with low inhibitory con‐
stants being found with derivatives of phosphinic amides, isoxazolones and the oxadia‐
zole-2-oxide chemotype (Furoxan) (Fig. 2) (Huang et al., 2012).
Preventive chemotherapy is the mainstay in the control of human soil-transmitted helmin‐
thiasis (STH). STH is primarily caused by the nematodes Ancylostoma duodenale and Necator
americanus (hookworms), Ascaris lumbricoides (roundworm) and Trichuris trichiura (whip‐
worm) that parasitize the human gastrointestinal tract. Four anthelminthics that exhibit a
broad spectrum of activity are currently recommended by the World Health Organization:
The benzimidazoles albendazole and mebendazole, the synthetic phenylimidazolthiazole le‐
vamisole and the pyrimidine derivative pyrantel pamoate. While benzimidazoles bind to
free β-tubulin, leading to tubule capping and degradation (Beech et al., 2011), the choliner‐
gic agonist levamisole activates ligand-gated acetylcholine receptors (Lewis et al., 1980) and
the pyrimidine derivative pyrantel pamoate induces persistent activation of nicotinic acetyl‐
choline receptors (Utzinger and Keiser, 2004). The GABA agonist piperazine, the nicotinic
acetylcholine receptor agonist tribendimidine are further drugs used in STH. Currently nei‐
ther drug class used to control or treat STH, has been implicated as influencing the redox
biology of parasites. Instead, most of the currently used or proposed drugs (Olliaro et al.,
2011) of gastro-intestinal nematodes affect ion channel function of the neuromuscular syn‐
apses. These neuroactive drugs cause paralysis of the worm and result in its rapid expulsion
or killing.
Filarial parasites are classified according to the habitat of the adult worms in the vertebral
host, with the cutaneous (Loa loa and Onchocerca volvulus) and lymphatic (Wuchereria bancrof‐
ti, Brugia malayi and Brugia timori) groups being the most clinically significant. Chemothera‐
peutic approaches to control parasite transmission and to treat onchocerciasis rely on the
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macrocyclic lactone ivermectin, an effective and safe microfilaricide (Basáňez et al., 2008).
Ivermectin is an agonist of ligand-gated Cl− channels, with particular activity against gluta‐
mate-gated Cl− channels of invertebrates (Martin et al., 1997). While ivermectin is less effec‐
tive against adult worms, it causes reproductive quiescence and disappearance of
microfilaria from skin or blood. Interestingly, cultured microfilariae are unaffected by iver‐
mectin at concentrations found in treated patients (Bennett et al., 1993), making interference
of the drug with protective mechanisms employed against the human immune response fea‐
sible (Geary et al., 2010). The development of ivermectin-resistant strains of Caenorhabditis
elegans has shown that resistance to low levels of ivermectin is associated with an increased
expression of drug efflux pumps and an increase in GSH-synthesis and -conjugation is ob‐
served. Since the overall levels of glutathione decrease, increased drug conjugation and re‐
moval from the cells is suggested (James and Davey, 2009). In a recent study, ivermectin has
been identified as a cytotoxic agent to leukemia cells and a previously unknown indirect in‐
fluence of ivermectin on the intracellular redox balance was demonstrated. Mechanistically,
ivermectin induced chloride influx, membrane hyperpolarization, and generated ROS, the
latter being functionally important for ivermectin-induced cell death (Shrameen et al., 2010).
Diethylcarbamazine (DEC) is still the mainstay for the treatment of lymphatic filariasis and
first choice of therapy of loiasis. Surprisingly, its molecular mechanism of action is still not
completely understood. Since pharmacologically relevant concentrations of DEC do not
have an effect on microfilariae in culture, its mode of action must involve both the worm
and its host. A possible involvement of host arachidonate- and NO-dependent pathways
was observed (McGarry et al., 2005). Currently no verification of an influence on the redox
biology of helminths is available.
It has been postulated that antioxidant enzymes, that defend against host-generated ROS,
are of particular importance for long-lived tissue-dwelling parasites that are involved in
chronic infections. Here, surface or secreted antioxidant enzymes are of great importance
since they can directly neutralize ROS that pose real danger, thereby protecting surface
membranes against peroxides. Secreted filarial antioxidant enzymes include SOD, GPx and
Prx (Henkle-Dührsen and Kampkötter, 2001). Additionally to their antioxidant role, the Prx
have recently been shown to contribute to the development of Th2-responses by altering the
function of macrophages (Donnelly et al., 2008). Interestingly, GSH-dependent proteins
have been observed that are capable of modifying the local environment via modulation of
the immune response. Here the secretory GSTs from O. volvulus combine several features
that make them excellent drug target: they are accessible since they are located directly at
the parasite–host interface, they detoxify and/or transport various electrophilic compounds
and secondary products of lipid peroxidation and they are involved in the synthesis of po‐
tential immunmodulators. Significant structural differences to the host homologues are ob‐
served in the xenobiotic binding site; this may support the structure-based design of specific
inhibitors (Sommer et al., 2003; Perbandt et al., 2008; Liebau et al., 2008).
As outlined above, GSH-dependent detoxification pathways defend against current drugs
and also play a role in mediating resistance to anthelmintics. The antioxidant pathways also
provide the parasite with a means to protect against ROS-attack by its host and/or vector. In
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the model nematode C. elegans, GSH-synthesis and a large variety of primary and secondary
antioxidant enzymes and GSH-dependent detoxification enzymes are tightly regulated by
the sole NF-E2-related (Nrf) transcription factor SKN-1 (An and Blackwell, 2003). Inhibiton
of SKN-1 would thus target the expression of a multitude of enzymatic antioxidants and de‐
toxification enzymes rather than affecting only one single protein or protein class, resulting
in the downregulation of xenobiotic detoxification and in an enormous increase of oxidative
stress. Since SKN-1 is also essential for embryonic development, this would be an additional
bonus. Nematode-specific structural differences are observed that make SKN-1 an excellent
candidate for the development of specific nematocidal drugs (Choe et al., 2012).
11. Conclusion
The current bottle-neck for the treatment of parasitic diseases with chemotherapeutics is the
increasing drug resistance which forces the continuous discovery and development of new
antiparasitic drugs. There is an urgent need for novel chemotherapeutic targets. New drugs
should be generated to specifically target the parasite with minimal (or no) toxicity to the
human host. Therefore, good drug targets should be distinctly different from processes in
the host, or ideally be absent in the latter. Targeting the peculiarities - which are absent in
the host - is proposed as such a strategy. In this sense, the parasite-specific biosyntheses rep‐
resent ideal drug targets; similar to the already exploited antifolate interference with the
parasite’s dihydrofolate (vitamin B9) biosynthesis. There are a variety of reports about reac‐
tive compounds that have antiparasitic activity; however, not all of these are therapeutically
viable drug-like molecules due to various limitations such as toxicity, low bioavailability,
rapid inactivation under in vivo conditions and development of resistance. Recently studies
on drug synergism raised special attention, which can open new avenues to improve the ef‐
ficacy of antiparasitic drugs in combination with others. Since parasites such as Plasmodium,
Trypanosoma or helminths are highly susceptible to oxidative stress - as outlined within this
chapter - the identification of new lead compounds that target the parasite’s redox systems
by inducing oxidative stress, will be an efficient approach to discover novel drugs.
In this chapter we have tried to give an outline of the present situation of redox-active anti‐
parasitic molecules that target human infectious diseases. In future the mechanisms, evolu‐
tionarily developed by the parasite to circumvent the crucial presence of ROS, will open
new avenues for the development of novel antiparasitic drugs that combat resistant human
pathogens effectively.
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